Forty states and Puerto Rico have signed agreements to join a federal Medicaid model that ties what state programs pay for certain brand-name drugs to prices in other wealthy countries, the Centers for Medicare & Medicaid Services announced Sept. 18. All 50 states, the District of Columbia, and Puerto Rico have applied, and the remaining states have until Sept. 30 to sign.
The White House has described the move as bringing lower drug prices to all 50 state Medicaid programs. That is accurate for applications, but a signed agreement is what commits a state to participate, and the final count will not be clear until the deadline passes.
For people covered by Medicaid, the most direct effect is likely on state and federal budgets rather than pharmacy receipts, since most enrollees already pay little or nothing for prescriptions. The more practical household questions involve which drugs states cover and under what rules.
Rebates Designed to Match Prices Abroad
Under the GENEROUS Model, participating drugmakers make covered outpatient drugs available to participating state Medicaid programs at most-favored-nation prices. States then bill manufacturers for supplemental rebates that bring the final price in line with international prices, according to CMS. The agency monitors pricing accuracy and shares in the savings by reducing the federal portion of Medicaid payments. The CMS model page lists participating states.
The model launched in January 2026 and runs for five years. The White House fact sheet says it includes hundreds of drugs across virtually all major drug classes, including cancer, diabetes, and asthma treatments. The administration has agreements with 26 manufacturers covering 89% of the branded drug market, according to the fact sheet.
CMS Administrator Dr. Mehmet Oz said, "Medicaid programs will get the best possible price for drugs," which he said would free up funds for other care. HHS Secretary Robert F. Kennedy Jr. said the model would drive down Medicaid drug costs and expand access, while CMS Innovation Center Director Abe Sutton said savings could let states invest more in other priorities.
The model grew out of a May 12, 2025, executive order directing the administration to bring U.S. drug prices in line with those paid in comparable countries.
Savings Estimates Come with Caveats
The White House Council of Economic Advisers estimates $64.3 billion in Medicaid drug savings over 10 years, with $36.6 billion going to the federal government and $27.6 billion to states. The administration has not published a state-by-state breakdown, so residents cannot yet see what their own state may save.
Outside experts are more cautious. Savings are hard to judge because the terms of the deals are not public, the Associated Press reported. Analysts quoted by STAT noted that the agreements mainly apply to Medicaid, which already receives some of the lowest drug prices of any U.S. payer because of federal rebate rules.
The administration also says Medicaid programs have received one million free prescriptions of the blood thinner Eliquis under its deals with drugmakers. That figure comes from the White House and has not been independently confirmed. The White House says the savings will free up money that states can invest in other programs.
What Enrollees and States Should Watch
Low-income families, children, older adults, and people with disabilities who rely on Medicaid are the model's intended beneficiaries. Those most likely to notice any change are enrollees taking brand-name drugs for conditions such as cancer, diabetes, or asthma, although CMS has not described how coverage rules might change in individual states.
Medicaid enrollees can watch for notices from their state Medicaid agency or managed care plan about formulary changes. Anyone told that a medicine is no longer preferred can ask a pharmacist or prescriber about alternatives, prior authorization, or an appeal. No one should stop a prescribed drug without talking with a clinician.
People not enrolled in Medicaid will not see direct changes from this model. Separate programs, such as the Medicare GLP-1 Bridge that MedicalDaily reported drew more than half a million enrollees in its first two months, operate under different rules.
The next milestone is Sept. 30, when the remaining states must sign to participate. Key open questions include which states sign, how each state carries out the model, and whether any contract terms become public. MedicalDaily will track the final participant list.
The bottom line is measured. The policy is real and broad, but its benefits flow mainly to government budgets for now, and the savings remain estimates rather than verified results.
Key Questions Answered
What did CMS announce? CMS said all 50 states, D.C., and Puerto Rico applied to the GENEROUS Medicaid drug pricing model, and 40 states plus Puerto Rico have signed agreements.
What is the Sept. 30 deadline? It is the date by which the remaining states must sign agreements with CMS to participate in the model.
How does the GENEROUS Model work? Participating drugmakers provide rebates to state Medicaid programs so the final price of included brand-name drugs does not exceed the most-favored-nation price paid in other developed countries.
How much money will it save? The White House Council of Economic Advisers estimates $64.3 billion over 10 years. No state-by-state estimate has been published, and outside experts say savings are hard to verify because deal terms are not public.
Will Medicaid enrollees pay less at the pharmacy? Most enrollees already pay little or nothing for prescriptions, so the main savings go to state and federal budgets.
What should Medicaid enrollees do now? Watch for notices from your state Medicaid agency or plan, and ask your pharmacist or prescriber about any formulary change before altering medication.
